PROVECTUS TO RECEIVE FIFTH MEDICAL DEVICE PATENT

Provectus Pharmaceuticals, Inc. announced today that it has received a notice of allowance for a patent application covering the Company's laser-based technologies for selective destruction of pigmented tissue, with applicability to elimination of moles and pigmented skin cancers, such as melanomas. The notice of allowance from the U.S. Patent and Trademark Office indicates that the application is in condition for issuance and a U.S. patent will be issued within several months.

Yahoo News (http://biz.yahoo.com/prnews/051222/nyth020.html?.v=34)